Cost-Effectiveness Analysis of Ubrogepant, Rimegepant, and Zavegepant for Acute Migraine Treatment vs Usual Care
The American Journal of Managed Care · 18.11.2025 · 31 (11) · e322
DOI: 10.37765/ajmc.2025.89822 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift The American Journal of Managed Care, online erschienen am 18.11.2025. Verfasst von Pooja Gokhale und 1 weiteren Autor:innen. Beteiligte Einrichtung: University of Georgia College of Pharmacy, 250 W Green St, Athens, GA 30602. Email: lorenzo.villazapata@uga.edu. Hauptthemen laut MEDLINE: Migraine Disorders, Pyridines, Calcitonin Gene-Related Peptide Receptor Antagonists, Piperidines. Die Arbeit wurde bisher 3-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- University of Georgia College of Pharmacy, 250 W Green St, Athens, GA 30602. Email: lorenzo.villazapata@uga.edu.
Zitieren
APA
Gokhale, P., & Villa Zapata, L. (2025). Cost-Effectiveness Analysis of Ubrogepant, Rimegepant, and Zavegepant for Acute Migraine Treatment vs Usual Care. The American Journal of Managed Care, 31(11), e322. https://doi.org/10.37765/ajmc.2025.89822
Vancouver
Gokhale P, Villa Zapata L. Cost-Effectiveness Analysis of Ubrogepant, Rimegepant, and Zavegepant for Acute Migraine Treatment vs Usual Care. The American Journal of Managed Care. 2025;31(11):e322. doi:10.37765/ajmc.2025.89822
BibTeX
@article{Gokhale2025,
author = {Gokhale, Pooja and Villa Zapata, Lorenzo},
title = {Cost-Effectiveness Analysis of Ubrogepant, Rimegepant, and Zavegepant for Acute Migraine Treatment vs Usual Care},
journal = {The American Journal of Managed Care},
year = {2025},
volume = {31},
number = {11},
pages = {e322},
doi = {10.37765/ajmc.2025.89822}
}
EUVIMED